November 25, 2016 - By Richard Conner · 0 Comments
The stock of Accelerate Diagnostics Incorporated (NASDAQ:AXDX) registered an increase of 0.86% in short interest. AXDX’s total short interest was 7.48M shares in November as published by FINRA. Its up 0.86% from 7.42 million shares, reported previously. With 251,800 shares average volume, it will take short sellers 30 days to cover their AXDX’s short positions. The short interest to Accelerate Diagnostics Incorporated’s float is 30.85%. The stock decreased 0.60% or $0.15 on November 23, hitting $25.05. Accelerate Diagnostics Inc (NASDAQ:AXDX) has risen 85.69% since April 22, 2016 and is uptrending. It has outperformed by 80.28% the S&P500.
Accelerate Diagnostics, Inc. is an in vitro diagnostics firm engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The company has a market cap of $1.28 billion. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. It currently has negative earnings. The Firm is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System , intended for the diagnosis of infectious pathogens.
Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.11, from 1.14 in 2016Q1. The ratio dropped, as 8 funds sold all Accelerate Diagnostics Inc shares owned while 28 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 12.54 million shares or 1.89% less from 12.78 million shares in 2016Q1.
Bnp Paribas Arbitrage Sa owns 1,157 shares or 0% of their US portfolio. Metropolitan Life New York owns 17,271 shares or 0% of their US portfolio. Edge Wealth Ltd has invested 0.01% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX). Qs Investors Limited accumulated 0% or 18 shares. Hightower Limited Company owns 13,062 shares or 0% of their US portfolio. Moreover, California Employees Retirement Sys has 0% invested in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 32,200 shares. The Massachusetts-based Geode Cap Ltd Liability Corporation has invested 0% in Accelerate Diagnostics Inc (NASDAQ:AXDX). Tru Com Of Vermont accumulated 1,000 shares or 0% of the stock. Voya Management Ltd Liability accumulated 0% or 10,707 shares. State Common Retirement Fund has invested 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX). Fairfield Bush And last reported 0.08% of its portfolio in the stock. Tower Rech Capital Ltd Com (Trc) holds 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 1,327 shares. Credit Suisse Ag last reported 0% of its portfolio in the stock. Alliancebernstein Limited Partnership accumulated 39,710 shares or 0% of the stock. Rtw Ltd Liability last reported 74,843 shares in the company.
Insider Transactions: Since June 8, 2016, the stock had 5 insider purchases, and 0 sales for $4.40 million net activity. Shares for $1.43 million were bought by SCHULER JACK W on Wednesday, June 8.
Out of 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Accelerate Diagnostics has been the topic of 5 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) earned “Outperform” rating by William Blair on Friday, January 8. The firm has “Neutral” rating given on Tuesday, August 25 by BTIG Research. The company was initiated on Wednesday, December 16 by Piper Jaffray. JP Morgan maintained Accelerate Diagnostics Inc (NASDAQ:AXDX) rating on Tuesday, August 9. JP Morgan has “Overweight” rating and $25 price target. On Thursday, March 24 the stock rating was initiated by JP Morgan with “Overweight”.
More important recent Accelerate Diagnostics Inc (NASDAQ:AXDX) news were published by: Nasdaq.com which released: “Accelerate Diagnostics to Present at the Piper Jaffray 28th Annual Healthcare …” on November 22, 2016, also Globenewswire.com published article titled: “Accelerate Diagnostics Submits De Novo Request to FDA for Accelerate Pheno …”, Benzinga.com published: “Cramer Likes Accelerate Diagnostics Inc” on April 03, 2016. More interesting news about Accelerate Diagnostics Inc (NASDAQ:AXDX) was released by: Seekingalpha.com and their article: “Accelerate Diagnostics: Potential Upside With Accelerated Pathogen Diagnostics” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner